Invesaro

Stocks Comparison

Airsculpt Technologies vs Oncology Institute: revenue, profit, margins and growth compared

Airsculpt Technologies brought in $151.8M of revenue in fiscal 2025, Oncology Institute $502.7M in fiscal 2025. Revenue changed by -15.8% at Airsculpt Technologies and +27.8% at Oncology Institute on the year before, so Oncology Institute grew faster. Airsculpt Technologies kept -7.7% of its revenue as net profit, Oncology Institute -12.1%. Free cash flow was $692K at Airsculpt Technologies and -$27.8M at Oncology Institute.

Side by side, latest fiscal year

AIRSTOI
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$151.8M$502.7M
Revenue growth-15.8%+27.8%
Net income-$11.7M-$60.6M
Net margin-7.7%-12.1%
Free cash flow$692K-$27.8M
Free cash flow margin0.5%-5.5%
Earnings per share (diluted)-$0.19-$0.54
Cash$8.4M$33.6M
Debt$56M$77.4M
Price to earningsn/an/a
Market value$135.5M$522.8M
Dividend yieldn/an/a
Rank by revenue in sector#293 of 742 · Health care#204 of 742 · Health care

Over the years

Revenue
AIRS FY2019: $41.2MAIRS FY2021: $62.8MAIRS FY2021: $133.3MAIRS FY2022: $168.8MAIRS FY2023: $195.9MAIRS FY2024: $180.4MAIRS FY2025: $151.8MTOI FY2020: $187.5MTOI FY2021: $203MTOI FY2022: $252.5MTOI FY2023: $324.2MTOI FY2024: $393.4MTOI FY2025: $502.7MFY19FY20FY21FY22FY23FY24FY25
AIRS $151.8MTOI $502.7M
Net income
AIRS FY2019: -$2.2MAIRS FY2021: $7.6MAIRS FY2021: $10.6MAIRS FY2022: -$14.7MAIRS FY2023: -$4.2MAIRS FY2024: -$8MAIRS FY2025: -$11.7MTOI FY2020: -$14.3MTOI FY2021: -$10.9MTOI FY2022: $152KTOI FY2023: -$83.1MTOI FY2024: -$64.7MTOI FY2025: -$60.6MFY19FY20FY21FY22FY23FY24FY25
AIRS -$11.7MTOI -$60.6M
Net margin
AIRS FY2019: -5.4%AIRS FY2021: 12.1%AIRS FY2021: 7.9%AIRS FY2022: -8.7%AIRS FY2023: -2.2%AIRS FY2024: -4.4%AIRS FY2025: -7.7%TOI FY2020: -7.6%TOI FY2021: -5.4%TOI FY2022: 0.1%TOI FY2023: -25.6%TOI FY2024: -16.4%TOI FY2025: -12.1%FY19FY20FY21FY22FY23FY24FY25
AIRS -7.7%TOI -12.1%
Revenue growth
AIRS FY2021: +52.2%AIRS FY2021: +112.4%AIRS FY2022: +26.6%AIRS FY2023: +16.1%AIRS FY2024: -7.9%AIRS FY2025: -15.8%TOI FY2021: +8.3%TOI FY2022: +24.4%TOI FY2023: +28.4%TOI FY2024: +21.3%TOI FY2025: +27.8%FY21FY22FY23FY24FY25
AIRS -15.8%TOI +27.8%
Free cash flow
AIRS FY2019: $499KAIRS FY2021: $10.3MAIRS FY2021: $19.5MAIRS FY2022: $11.5MAIRS FY2023: $14MAIRS FY2024: -$2.7MAIRS FY2025: $692KTOI FY2020: -$686KTOI FY2021: -$35.5MTOI FY2022: -$67.3MTOI FY2023: -$40.9MTOI FY2024: -$30.3MTOI FY2025: -$27.8MFY19FY20FY21FY22FY23FY24FY25
AIRS $692KTOI -$27.8M

Fiscal years as each company reports them; the two may end in different months.

Questions about Airsculpt Technologies and Oncology Institute

Which is bigger by revenue, Airsculpt Technologies or Oncology Institute?

Oncology Institute is bigger by revenue: $502.7M in fiscal 2025, against $151.8M for Airsculpt Technologies in fiscal 2025.

Which keeps more of its revenue as profit, Airsculpt Technologies or Oncology Institute?

Airsculpt Technologies had a net margin of -7.7% in fiscal 2025; Oncology Institute had -12.1% in fiscal 2025.

Which grew revenue faster, Airsculpt Technologies or Oncology Institute?

In their latest fiscal years revenue changed by -15.8% at Airsculpt Technologies and +27.8% at Oncology Institute.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies